Analyst
Goldman Sachs
Equibles does not estimate personal net worth.
Corrine Johnson is recorded as Analyst at Goldman Sachs. Corrine Johnson has spoken on 4 earnings calls and 2 other investor events across 4 companies, most recently for Geron Corp on June 8, 2026. Those appearances were for Geron Corp (GERN), Halozyme Therapeutics, Inc. (HALO), Fulcrum Therapeutics, Inc. (FULC) and Tg Therapeutics, Inc. (TGTX). The companies whose calls Corrine Johnson spoke on are classified in the Healthcare sector.
“We're thrilled to have the team from GERON here this morning. And maybe with that, Harud, I'm just going to turn it straight to you. I'd love for you to kind of walk through what you view as an overview of the company and key value drivers for the business over the next, let's call it, 12 to 24 months.”
“Maybe you could just kind of spend some time walking us through the development timelines after you get into Phase 1 with HyperCon, I guess early next year now, and sort of how do you kind of get to the potential approval then in a three- to four-year timeline from there?”
“Maybe a question for us in just kind of the competitive landscape and evolving, you know, treatment landscape in sickle cell disease. I guess, could you help us think through the role you expect POSER to play, particularly if there's more kind of oral medications that come to market over the next couple of years?”
“Maybe continue on the conversation on SIPQ. Some of the competitors in the space have started providing color on the role they think a SIPQ offering could play over time with respect to IV versus SIPQ share.”
“You mentioned that you have approximately 30% of patients in that first and second line setting that are currently on therapy. Could you help us think through what that needs to be in order to reach your guidance for the year?”
Goldman Sachs
Analyst
Transcript header (unverified)
GERN
Biotechnology · Healthcare
